Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes

British Journal of Pharmacology

Volumn 168, Issue 7, 2013, Pages 1662-1674

  Watts, A O ^a   Van Lipzig, M M H ^a   Jaeger, W C ^d   Seeber, R M ^d   Van Zwam, M ^b   Vinet, J ^b   Van Der Lee, M M C ^c   Siderius, M ^a   Zaman, G J R ^c,f   Boddeke, H W G M ^b   Smit, M J ^a   Pfleger, K D G ^d,e   Leurs, R ^a   Vischer, H F ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e Dimerix Bioscience Pty Ltd   (Australia)

^f Netherlands Translational Research Center BV   (Netherlands)

Author keywords

arrestin; chemokine receptor; CXCR3; CXCR4; GPCR; heteromerization; radioligand binding

Indexed keywords

BETA ARRESTIN; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; CELL SURFACE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ARRESTINS; CELL MEMBRANE; CHEMOKINE CXCL10; CHEMOKINE CXCL12; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; LIGANDS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RADIOLIGAND ASSAY; RECEPTORS, CXCR3; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION;

EID: 84875187354     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12064     Document Type: Article

References (48)

1. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al,. (1999). A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 96: 5698-5703.
2. Babcock GJ, Farzan M, Sodroski J, (2003). Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J Biol Chem 278: 3378-3385.
3. Birdsall NJ, (2010). Class A GPCR heterodimers: evidence from binding studies. Trends Pharmacol Sci 31: 499-508.
4. Chabre M, Deterre P, Antonny B, (2009). The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci 30: 182-187.
5. Christopoulos A, Lanzafame A, Ziegler A, Mitchelson F, (1997). Kinetic studies of co-operativity at atrial muscarinic M2 receptors with an 'infinite dilution' procedure. Biochem Pharmacol 53: 795-800.
6. Contento RL, Molon B, Boularan C, Pozzan T, Manes S, Marullo S, et al,. (2008). CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci U S A 105: 10101-10106.
7. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, et al,. (2001). Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59: 707-715.
8. De Lean A, Stadel JM, Lefkowitz RJ, (1980). A ternary complex model explains the agonist-specific binding properties of the adenylyl cyclase-coupled b-adrenergic receptor. J Biol Chem 255: 7108-7117.
9. Dorsch S, Klotz KN, Engelhardt S, Lohse MJ, Bunemann M, (2009). Analysis of receptor oligomerization by FRAP microscopy. Nat Methods 6: 225-230.
10. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, Parmentier M, (2005). Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 67: 460-469.
11. Fulton AM, (2009). The chemokine receptors CXCR4 and CXCR3 in cancer. Curr Oncol Rep 11: 125-131.
12. Hamatake M, Aoki T, Futahashi Y, Urano E, Yamamoto N, Komano J, (2009). Ligand-independent higher-order multimerization of CXCR4, a G-protein-coupled chemokine receptor involved in targeted metastasis. Cancer Sci 100: 95-102.
13. Hern JA, Baig AH, Mashanov GI, Birdsall B, Corrie JE, Lazareno S, et al,. (2010). Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc Natl Acad Sci U S A 107: 2693-2698.
14. Issafras H, Angers S, Bulenger S, Blanpain C, Parmentier M, Labbe-Jullie C, et al,. (2002). Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem 277: 34666-34673.
15. Jahnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, et al,. (2010). CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A 107: 20565-20570.
16. Jalink K, Van Rheenen J, (2009). FilterFRET: quantitative imaging of sensitized emission. In:, Gadella TW, Jr, (ed.). Fret and Flim Techniques, Vol. 33. Academic Press: Burlington, MA, pp. 289-349.
17. Johnson M, Li AR, Liu J, Fu Z, Zhu L, Miao S, et al,. (2007). Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 17: 3339-3343.
18. Lacotte S, Brun S, Muller S, Dumortier H, (2009). CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 1173: 310-317.
19. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B, (2009). CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113: 6085-6093.
20. Luker KE, Gupta M, Luker GD, (2009). Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J 23: 823-834.
21. Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM, (2008). In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochem Res 33: 2142-2150.
22. Mercier JF, Salahpour A, Angers S, Breit A, Bouvier M, (2002). Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem 277: 44925-44931.
23. Moser B, Loetscher P, (2001). Lymphocyte traffick control by chemokines. Nat Immunol 2: 123-128.
24. Mustafa S, Pfleger KD, (2011). G protein-coupled receptor heteromer identification technology: identification and profiling of GPCR heteromers. J Lab Autom 16: 285-291.
25. Mustafa S, See HB, Seeber RM, Armstrong SP, White CW, Ventura S, et al,. (2012). Identification and profiling of novel alpha1A-adrenoceptor-CXC chemokine receptor 2 heteromer. J Biol Chem 287: 12952-12965.
26. Nijmeijer S, Leurs R, Smit MJ, Vischer HF, (2010). The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Galphai proteins, and constitutively impairs CXCR4 functioning. J Biol Chem 285: 29632-29641.
27. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, et al,. (2005). Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 280: 9895-9903.
28. Pfleger KD, Dromey JR, Dalrymple MB, Lim EM, Thomas WG, Eidne KA, (2006a). Extended bioluminescence resonance energy transfer (eBRET) for monitoring prolonged protein-protein interactions in live cells. Cell Signal 18: 1664-1670.
29. Pfleger KD, Seeber RM, Eidne KA, (2006b). Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nat Protoc 1: 337-345.
30. van Rheenen J, Langeslag M, Jalink K, (2004). Correcting confocal acquisition to optimize imaging of fluorescence resonance energy transfer by sensitized emission. Biophys J 86: 2517-2529.
31. van Rijn RM, Chazot PL, Shenton FC, Sansuk K, Bakker RA, Leurs R, (2006). Oligomerization of recombinant and endogenously expressed human histamine H(4) receptors. Mol Pharmacol 70: 604-615.
32. Scholten D, Canals M, Maussang D, Roumen L, Smit M, Wijtmans M, et al,. (2012a). Pharmacological modulation of chemokine receptor function. Br J Pharmacol 165: 1617-1643.
33. Scholten D, Canals M, Wijtmans M, de, Munnik S, Nguyen P, Verzijl D, et al,. (2012b). Pharmacological characterisation of a small-molecule agonist for the chemokine receptor CXCR3. Br J Pharmacol 166: 898-911.
34. See HB, Seeber RM, Kocan M, Eidne KA, Pfleger KD, (2011). Application of G protein-coupled receptor-heteromer identification technology to monitor beta-arrestin recruitment to G protein-coupled receptor heteromers. Assay Drug Dev Technol 9: 21-30.
35. Sohy D, Parmentier M, Springael JY, (2007). Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem 282: 30062-30069.
36. Sohy D, Yano H, de, Nadai P, Urizar E, Guillabert A, Javitch JA, et al,. (2009). Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of 'selective' antagonists. J Biol Chem 284: 31270-31279.
37. Springael JY, Le Minh PN, Urizar E, Costagliola S, Vassart G, Parmentier M, (2006). Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol 69: 1652-1661.
38. Stroke IL, Cole AG, Simhadri S, Brescia MR, Desai M, Zhang JJ, et al,. (2006). Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries. Biochem Biophys Res Commun 349: 221-228.
39. Tanaka T, Nomura W, Narumi T, Masuda A, Tamamura H, (2010). Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells. J Am Chem Soc 132: 15899-15901.
40. Vandercappellen J, Van Damme J, Struyf S, (2008). The role of CXC chemokines and their receptors in cancer. Cancer Lett 267: 226-244.
41. Verzijl D, Storelli S, Scholten DJ, Bosch L, Reinhart TA, Streblow DN, et al,. (2008). Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. J Pharmacol Exp Ther 325: 544-555.
42. Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, Lohse MJ, (2008). Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol 4: 126-131.
43. Viola A, Luster AD, (2008). Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 48: 171-197.
44. Vischer HF, Nijmeijer S, Smit MJ, Leurs R, (2008). Viral hijacking of human receptors through heterodimerization. Biochem Biophys Res Commun 377: 93-97.
45. Vischer HF, Watts AO, Nijmeijer S, Leurs R, (2011). G protein-coupled receptors: walking hand-in-hand, talking hand-in-hand? Br J Pharmacol 163: 246-260.
46. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, et al,. (2005). A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc Natl Acad Sci U S A 102: 9050-9055.
47. Wijtmans M, Verzijl D, Leurs R, de, Esch IJ, Smit MJ, (2008). Towards small-molecule CXCR3 ligands with clinical potential. ChemMedChem 3: 861-872.
48. Wilson S, Wilkinson G, Milligan G, (2005). The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. J Biol Chem 280: 28663-28674.